New Mexico Accelerates Psilocybin Therapy Program Launch to December 2026, New Jersey Approves Hospital-Based Pilot
Key Insights
New Mexico health officials announced plans to launch their medical psilocybin therapy program by December 2026, one year ahead of the original legislative deadline, targeting treatment-resistant depression (search), PTSD (search), substance use disorders (search), and end-of-life care.
New Jersey Governor Murphy signed Bill 2830 this week, establishing a $6 million pilot program at three hospitals to develop psilocybin therapy protocols based on FDA study designs over a two-year data collection period.
Both states join Oregon and Colorado in pioneering therapeutic psilocybin access, with each implementing distinct regulatory models ranging from wellness-focused services to medical center-based treatments.
New Mexico health officials have announced plans to launch the state's medical psilocybin therapy program by the end of December 2026—a full year ahead of the legislative deadline. This expedited timeline was revealed on December 5, during the public first meeting of the state's Medical Psilocybin Advisory Board, established by Senate Bill 219 earlier in 2025.
The program is designed to provide treatment for specific qualifying conditions, including major treatment-resistant depression (search), PTSD (search), substance use disorders (search) and end-of-life care. According to Dr. Dominick Zurlo, director of the Center for Medical Cannabis and Psilocybin, New Mexico's Department of Health has already appointed a program manager and is actively recruiting for an environmental scientist and a compliance officer.
"Because there has been such large interest in this and a push for us to try to be able to help people with psilocybin treatments earlier, we have set a goal now to have the program at least to be able to see the initial patients by the end of December of 2026," said Zurlo in his opening remarks at the meeting.
New Jersey Launches Hospital-Based Pilot Program
Meanwhile, New Jersey has taken a different approach with outgoing Governor Murphy signing Bill 2830 this week, paving the way for three chosen New Jersey hospitals to develop psilocybin therapy pilot programs. The legislation allocates $6 million in funds to create a psilocybin therapy program based on protocols used in FDA studies, with data collection over a two-year period to inform next steps.
New Jersey's pilot programs will be located in three chosen hospitals and will emphasize careful attention to medical and psychiatric screening, intentional use for mental health disorders, and therapy support around preparing and integrating the psychedelic experience. The bill does not legalize recreational use of psilocybin.
Diverse State Models Emerge
Each state implementing psilocybin therapy has adopted distinct regulatory approaches. Oregon removes psilocybin from the medical model and refers to it as a service with an emphasis on wellness. New Mexico, like New Jersey, is embracing a medical model, but not in a hospital setting, emphasizing clinical access at specialized psilocybin centers. New Jersey focuses on gathering data through its hospital-based pilot program.
State Senator Jeff Steinborn (D), a co-sponsor of New Mexico's bill, described the initiative as part of a "new renaissance of psychedelic medicine" and encouraged innovation beyond what other states have implemented. "I wanna challenge you to not be afraid to innovate, to make things better than maybe they've been in other states," he said during the inaugural board meeting.
Balancing Speed with Safety and Equity
While public interest has driven decisions to accelerate timelines, advocates are urging caution. Denali Wilson, New Mexico Director of Strategic Support for the Healing Advocacy Fund (search), emphasized the importance of balancing urgency with safety, affordability and ethics.
"Let's be sure that any acceleration of the regulatory timeline doesn't unintentionally compromise patient safety, undermine long-term sustainability or limit meaningful public engagement," Wilson said during the meeting.
The Healing Advocacy Fund (search), which has played significant roles in Oregon and Colorado's programs where affordability remains a barrier, highlighted New Mexico's economic disparities. Wilson urged full funding of the program's equity fund and suggested innovative policy solutions including "allowing group-care models, adopting a broad definition of 'clinician' within the rules, authorizing diverse care settings and care teams, including peer support workers and traditional healers."
FDA Approval Timeline
The variety of state bills supporting psilocybin therapy may inspire other states, though many are waiting to see whether psilocybin will be rescheduled and FDA-approved. The FDA categorized psilocybin as "a breakthrough therapy" in 2018 for depression (search), and with psilocybin now in the final stage of FDA trials, many believe there is a solid chance it will be rescheduled and FDA-approved to treat major depression and treatment-resistant depression as early as this year or next.
Implementation Challenges
Community leaders acknowledge the logistical challenges ahead. Deborah Thorne, founder of Sol Tryp (search), a Las Cruces-based nonprofit, noted that faster rollout "will require a significant amount of dedication and hours by the advisory board to establish rules and regulations." She emphasized the need for comprehensive training programs for facilitators and prescribers, and establishing vetted facilities across New Mexico municipalities.
New Mexico's Medical Psilocybin Advisory Board includes seven members selected after a lengthy application process, tasked with creating regulatory guardrails while protecting patients. The board's composition reflects goals of equitable access and cultural sensitivity, including Indigenous advocate DezBaa (Sharon Henderson), who aims to ensure the framework honors traditional healing methodologies.
The board's next public meeting is scheduled for December 12, as New Mexico positions itself to potentially lead the integration of psychedelic therapy into existing healthcare systems.